Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,905.89 -947.74 (-1.46%) CMC Crypto 200
1,332.30 -64.24 (-4.60%)
Xeris Biopharma Holdings, Inc. (XERS)
After hours:
- Zacks
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions
Key Insights The considerable ownership by retail investors in Xeris Biopharma Holdings indicates that they...
- Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO, April 03, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris’ Inducement Equity Plan.
